News and Media

Latest News Release
04/13/2021

Cardinal Health (NYSE: CAH) was awarded a $57.8 million contract, including options that if exercised by the U.S. Department of Health and Human Services (HHS) could reach $91.6 million, for the...

Top feature box IMAGE ONLY - COMPANY NEWS

Company News

Cardinal Health to Webcast Discussion of Third-Quarter Results for Fiscal Year 2021 on May 6
03/30/2021

DUBLIN, Ohio, March 30, 2021 /PRNewswire/ -- Cardinal Health (NYSE: CAH) plans to release third-quarter financial results for its fiscal year 2021 on May 6 prior to the opening of trading on the New York Stock Exchange. The company will webcast a discussion of these results beginning at 8:30 a.m. Eastern.

To access the webcast and corresponding slide presentation, go to the Investor Relations page at ir.cardinalhealth.com. No access code is required.  Presentation slides and a webcast replay will be available until May 5, 2022.

About Cardinal Health
Cardinal Health is a distributor of pharmaceuticals, a global manufacturer and distributor of medical and laboratory products, and a provider of performance and data solutions for health care facilities. With 50 years in business, operations in more than 40 countries and approximately 48,000 employees globally, Cardinal Health is essential to care. Information about Cardinal Health is available at cardinalhealth.com.

Media: 

Sarah Shew


(614) 553-3401


Sarah.Shew@cardinalhealth.com



Investors: 

Kevin Moran


(614) 757-7942


Kevin.Moran@cardinalhealth.com

 

SOURCE Cardinal Health

More Company News
06/10/2021

Cardinal Health (NYSE: CAH) today announced that LYMPHOSEEK® (technetium Tc 99m tilmanocept) injection – the first and only radiopharmaceutical agent specifically designed for targeted...

06/09/2021

By Victor Crawford, Chief Executive Officer, Pharmaceutical Segment

06/03/2021

By Tiffany Olson, president of Nuclear & Precision Health Solutions at Cardinal Health. From HealthCare Business News magazine: Precision medicine is an area of healthcare that targets treatment...

06/03/2021

Four years after the approval of the first CAR-T cell therapies, oncologists are referring more patients for treatment and becoming more comfortable with the cost. However, payer approvals and...

View all company news »

* Required Fields